CAR T (Chimeric Antigen Receptor-T Cell)
Sorrento’s cellular therapy programs focus on Chimeric Antigen Receptor-T Cell (CAR T) for adoptive cellular immunotherapy to treat both solid and liquid tumors.
The CAR T program includes CD38, CEA and CD123.
Sorrento’s CD38 CAR T targets high-expressing CD38 positive cells, which may limit on-target/off-tumor toxicity.
The company’s CD38 CAR T candidate is currently being evaluated in multiple myeloma (MM). The program has successfully demonstrated strong preclinical anti-tumor activity in animal models and is currently in phase 1 trial in RRMM. Additionally, Sorrento has reported data from Phase I trials of carcinoembryonic antigen (CEA) directed CAR T program.
The company is assessing CD123 CAR T in acute myeloid leukemia (AML).
DAR T (Dimeric Antigen Receptor-T Cell)
Sorrento utilizes a proprietary knock-out knock-in (KOKI) technology to modify normal healthy donor derived T cells to genetically engineer them to express the dimeric antigen receptor into T-cell receptor (TCR) alpha chain constant region (TRAC). In this manner, TRAC is knocked out and antigen is knocked into its locus.
The Dimeric Antigen Receptor (DAR) utilizes a Fab instead of the scFv used by traditional Chimeric Antigen Receptor (CAR) T cells. We believe this DAR has been demonstrated in preclinical studies greater specificity, stability and potency.